Centessa Pharmaceuticals Pricing Public Offering of American Depositary Shares
Centessa Pharmaceuticals Pricing Public Offering
BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced the pricing of its upsized public offering of American Depositary Shares (ADS).
Details of the Offering
- Amount: $225 million
- ADS: Each ADS represents a certain number of shares of common stock.
The funds raised will be directed towards advancing the company’s pipeline of innovative therapeutics and expanding its research capabilities.
Significance in the Pharmaceutical Sector
This substantial offering positions Centessa as a pivotal player in the healthcare industry, aimed at fulfilling unmet medical needs through innovative drug development.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.